Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL461023 | 0.85 | ALDH1A1 (0.46) | KDM4EALDH1A1HPGDMAPTHSD17B10 | |
| SCHEMBL11036461 | 0.84 | AKT1 (0.42) | KDM4EALDH1A1HPGDMAPTTSHR | |
| SCHEMBL4863926 | 0.83 | KEAP1 (0.36) | KDM4EALDH1A1HPGDMAPTTSHR | |
| SCHEMBL7197042 | 0.81 | KDM4E (0.44) | KDM4EALDH1A1HPGDMAPTTSHR | |
| SCHEMBL2212689 | 0.81 | MAPT (0.49) | ALDH1A1MAPTHSD17B10LMNAGAA | |
| SCHEMBL7624006 | 0.79 | KDM4E (0.46) | KDM4EALDH1A1HPGDMAPTTSHR | |
| SCHEMBL3210135 | 0.79 | KDM4E (0.46) | KDM4EALDH1A1HPGDMAPTTSHR | |
| SCHEMBL20077832 | 0.78 | ADRA2A (0.30) | — | |
| SCHEMBL9542306 | 0.77 | KDM4E (0.41) | KDM4EALDH1A1HPGDMAPTTSHR | |
| SCHEMBL666673 | 0.77 | DPP4 (0.33) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003055857-A1 | A PROCESS FOR SYNTHESIS OF HETEROCYCLIC AMINOALKYL BENZAMIDES | FARMACEUTSKO-HEMIJSKA INDUSTRIJA 'ZDRAVLJE' (YU) | 2003-07-10 | — | — | WO | claimed |
| US-20090286876-A1 | NEUROPROTECTIVE BENZOATE AND BENZAMIDE COMPOUNDS | SAMARITAN PHARMACEUTICALS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20060167108-A1 | Neuroprotective benzoate and benzamide compounds | GEORGETOWN UNIVERSITY | 2006-07-27 | — | — | US | disclosed |
| EP-1628649-A2 | NEUROPROTECTIVE BENZOATE AND BENZAMIDE COMPOUNDS | Samaritan Pharmaceuticals (US) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004108666-A2 | NEUROPROTECTIVE BENZOATE AND BENZAMIDE COMPOUNDS | SAMARITAN PHARMACEUTICALS, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| WO-2003055857-A8 | A PROCESS FOR SYNTHESIS OF HETEROCYCLIC AMINOALKYL BENZAMIDES | FARMACEUTSKO HEMIJSKA IND ZDRA (YU) | 2003-10-30 | — | — | WO | disclosed |
| WO-2003055857-A8 | A PROCESS FOR SYNTHESIS OF HETEROCYCLIC AMINOALKYL BENZAMIDES | FARMACEUTSKO HEMIJSKA IND ZDRA (YU) | 2003-10-30 | — | — | WO | disclosed |
| WO-2003055857-A1 | A PROCESS FOR SYNTHESIS OF HETEROCYCLIC AMINOALKYL BENZAMIDES | FARMACEUTSKO-HEMIJSKA INDUSTRIJA 'ZDRAVLJE' (YU) | 2003-07-10 | — | — | WO | disclosed |
| WO-2003055857-A1 | A PROCESS FOR SYNTHESIS OF HETEROCYCLIC AMINOALKYL BENZAMIDES | FARMACEUTSKO-HEMIJSKA INDUSTRIJA 'ZDRAVLJE' (YU) | 2003-07-10 | — | — | WO | disclosed |
| WO-2003055857-A1 | A PROCESS FOR SYNTHESIS OF HETEROCYCLIC AMINOALKYL BENZAMIDES | FARMACEUTSKO-HEMIJSKA INDUSTRIJA 'ZDRAVLJE' (YU) | 2003-07-10 | — | — | WO | disclosed |
| WO-1999006376-A1 | NOVEL SULPHONAMIDE DERIVED FROM SUBSTITUTED ANILINES USEFUL AS MEDICINES | PIERRE FABRE MEDICAMENT (FR) | 1999-02-11 | — | — | WO | disclosed |
| EP-0817630-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-01-27 | — | — | EP | disclosed |
| EP-0817630-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-01-14 | — | — | EP | disclosed |
| US-5578629-A | ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1996-11-26 | — | — | US | disclosed |
| US-5578629-A | ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1996-11-26 | — | — | US | disclosed |
| WO-1996030015-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| US-5534537-A | Prodrugs of inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1996-07-09 | — | — | US | disclosed |
| US-5534537-A | Prodrugs of inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1996-07-09 | — | — | US | disclosed |
| US-4207327-A | N-(4-Pyrazolidinyl)benzamides and their amino precursors | A. H. ROBINS COMPANY, INC. (US) | 1980-06-10 | — | — | US | disclosed |
| US-3342826-A | Heterocyclic aminoalkyl benzamides | ILE DE FRANCE | 1967-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286876-A1 | NEUROPROTECTIVE BENZOATE AND BENZAMIDE COMPOUNDS | ABAT, GABRB2, GABRB1 | KDM4E 2613/4885ALDH1A1 590/4885HPGD 1284/4885 |
| US-20060167108-A1 | Neuroprotective benzoate and benzamide compounds | ABAT, GABRB2, GABRB1 | KDM4E 2613/4885ALDH1A1 590/4885HPGD 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.